TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7575897
Drug: Saline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions (previous study)
Study: 786694
Drug: Salmefamol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmefamol 1 mg
Study: 786694
Drug: Salmefamol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmefamol 2 mg
Study: 28068987
Drug: Acetyl-DL-leucine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-DL-leucine (up to 5 g per day)
Study: 24083628
Drug: Facial massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial massage therapy
Study: 19488741
Drug: Nicotine (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (14 mg for smokers, 7 mg for nonsmokers)
Study: 12527540
Drug: Cognitive/Behavioral Therapy-Alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive/Behavioral Therapy-Alone (C/B-Alone)
Study: 9345325
Drug: HFX/PE (Hyperfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX/PE (Hyperfractionated radiation therapy with concurrent chemotherapy)
Study: 9345325
Drug: HFX (Hyperfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX (Hyperfractionated radiation therapy alone)
Study: 3954817
Drug: Drugs from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs from 7 psychopharmacological classes
Study: 31234234
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist intervention via home medication management review (HMMR)
Study: 27020070
Drug: Oxytocin treatment
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin treatment (placebo)
Study: 27020070
Drug: Serotonin treatment
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin treatment (placebo)
Study: 8620707
Drug: No rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rehabilitation therapy (Control group)
Study: 2011430
Drug: Methylphenidate 5
Normalized name: dexmethylphenidate 5.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 5 mg twice a day
Study: 2011430
Drug: Methylphenidate 10
Normalized name: dexmethylphenidate 10.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 10 mg twice a day
Study: 2011430
Drug: Methylphenidate 15
Normalized name: METHYLPHENIDATE 15MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 15 mg twice a day
Study: 2011430
Drug: Moderate to
Normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate to high dose of methylphenidate
Study: 30053298
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate supplementation to maintain venous bicarbonate levels at 24-26 mEq/L along with standard care as per KDIGO 2012 guidelines
Study: 30053298
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm with oral sodium bicarbonate supplementation
Study: 8610232
Drug: Vinorelbine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (single agent)
Study: 8610232
Drug: Vindesine/Cisplatin (combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine/Cisplatin (combination)
Study: 8610232
Drug: Vinorelbine/Cisplatin (combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine/Cisplatin (combination)
Study: 7044797
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg t.i.d.
Study: 7044797
Drug: Benoxaprofen 600
Normalized name: fenoprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 600 mg once daily
Study: 23983157
Drug: Nontraditional retention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontraditional retention strategy - school administration assistance
Study: 15226663
Drug: e-AGV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-AGV group (AGV implant surgery using pericardial membrane)
Study: 15226663
Drug: AGV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGV group (AGV implant surgery without surface area extension)
Study: 12190806
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) 2 ml i.v.
Study: 12190806
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 30 s
Study: 12190806
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 60 s
Study: 12190806
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 120 s
Study: 12190806
Drug: Ketorolac 15
Normalized name: ketorolac 15.75 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 15 mg in 2 ml NS with propofol injection after 60 s
Study: 12190806
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg in 2 ml NS with propofol injection after 60 s
Study: 9694611
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/day for 2 years (postmenopausal)
Study: 9694611
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (TAM + MMC + CPA)
Study: 2527044
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10.0 mg/d) in combination with HCTZ (50 mg/d)
Study: 2527044
Drug: HCTZ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (50 mg/d) with placebo
Study: 31539295
Drug: Single-agent panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-agent panitumumab
Study: 28536206
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg dextrose gel
Study: 17999976
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 600 mg linezolid
Study: 17999976
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of linezolid (extrapolated)
Study: 15713524
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1, 8, 15, every 28 days (arm Q4W)
Study: 15713524
Drug: Gemcitabine 1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1125 mg/m2 on days 1 and 8, every 21 days (arm Q3W)
Study: 9794735
Drug: Lacidipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (calcium antagonist)
Study: 9097789
Drug: PRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP treatment after TC‐INV/ANV developed
Study: 9097789
Drug: PRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP treatment after TC‐INV/ANV developed (previously treated eyes)
Study: 31512365
Drug: metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin plus lifestyle intervention (LSI)
Study: 31512365
Drug: metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 850 mg once daily for the first 2 weeks, then twice daily thereafter
Study: 29362047
Drug: Dexmedetomidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2 mcg/kg/hour)
Study: 27978912
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment using periodontal endoscope
Study: 27978912
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment method (control group)
Study: 12011683
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with cytokine adjuvants, peeling of the internal limiting membrane, vital staining with indocyanine green dye, variations in postoperative face-down positioning
Study: 9642895
Drug: Both forms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both forms of therapy
Study: 1217691
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic medications (Control)
Study: 30892806
Drug: Digitoxin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitoxin (target serum concentration 8-18 ng/mL)
Study: 28224950
Drug: Injection-site splinting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection-site splinting (experimental group)
Study: 28224950
Drug: No injection-site
Normalized name: No Dolo Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No injection-site splinting (control group)
Study: 26027223
Drug: Reamberin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin 1.5% (succinate‐containing infusion solution)
Study: 21422859
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g administered 30-60 minutes before skin incision
Study: 15127162
Drug: Thêta-Cream
Normalized name: menthol / methyl salicylate Topical Cream [Thera-Gesic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thêta-Cream
Study: 15127162
Drug: Bepanthol lotion
Normalized name: Bepantol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepanthol lotion
Study: 9915106
Drug: Basal (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal (no drug administration)
Study: 30613020
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation (loading dose of 0.6 mg·kg‐1·h‐1 followed by maintenance dose of 3 mg·kg‐1·h‐1)
Study: 22820601
Drug: RhTPO (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhTPO (1.0 µg/kg) administered subcutaneously daily for 7 days starting 3 days before the second chemotherapy cycle (Group A)
Study: 22820601
Drug: RhTPO (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhTPO (1.0 µg/kg) administered daily for 7 days starting 6-24 hours after the second chemotherapy cycle (Group B)
Study: 22820601
Drug: Control cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycle (no RhTPO administered during the first chemotherapy cycle)
Study: 12930046
Drug: Self‐administered Client
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered Client Perceptions of Coordination Questionnaire
Study: 8241701
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 therapy
Study: 8241701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients without coenzyme Q10 therapy)
Study: 4089312
Drug: Acipimox (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (3 X 250 mg/day)
Study: 31100534
Drug: GIP (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIP (200 μg)
Study: 31100534
Drug: GLP-2 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 (800 μg)
Study: 31100534
Drug: GIP(3-30)NH2 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIP(3-30)NH2 (800 pmol/kg/min) + GLP-2 (800 μg)
Study: 25383369
Drug: Electromyography-guided botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyography-guided botulinum toxin injection
Study: 25383369
Drug: Fiberscopy-guided botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiberscopy-guided botulinum toxin injection
Study: 22490651
Drug: Mifepristone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (various doses)
Study: 22490651
Drug: Mifepristone (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (high dose)
Study: 17906182
Drug: Walnut-supplemented diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-supplemented diet (mean 35 grams daily, 12% total energy)
Study: 12188483
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of steroid (20 mg of triamcinolone with lignocaine)
Study: 12188483
Drug: Extracorporeal shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal shock-wave therapy (2000 shock waves in three sessions at weekly intervals)
Study: 10457271
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg daily for 1 year)
Study: 19284933
Drug: Vilazodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (10 mg to 40 mg once a day for 8 weeks)
Study: 8392261
Drug: Essential fatty
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential fatty acids treatment
Study: 28623089
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 0.5% (12.6mg) with 15μg fentanyl and 75μg morphine
Study: 28623089
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 0.5% (6.0mg) with 15μg fentanyl and 75μg morphine
Study: 28623089
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of bupivacaine
Study: 15566506
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b plus ribavirin (100 microg once weekly and 800 mg/day orally)
Study: 15566506
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b plus ribavirin (3 million units thrice weekly and 800 mg/day)
Study: 3336176
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin applied to forearm
Study: 3336176
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin applied to face
Study: 3336176
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied to forearm
Study: 3336176
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied to face
Study: 26665460
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg by muscle injection 30 min before the operation followed by saline every 24 h for 48 h (Group A)
Study: 26665460
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg by muscle injection 30 min before the operation followed by 40 mg every 24 h for 48 h (Group B)
Study: 23905652
Drug: Black pepper
Normalized name: Black Pepper
DrugBank: Black pepper (DB10557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black pepper (2.0 g)
Study: 23905652
Drug: Rosemary (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosemary (1.7 g)
Study: 23905652
Drug: Placebo (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.1 g rice flour)
Study: 21692235
Drug: Lornoxicam (LNX)
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (LNX) 8 mg
Study: 21692235
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (DP) 50 mg
Study: 14727000
Drug: Fluoxetine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 30 mg daily
Study: 11395188
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg/day for 3 days)
Study: 8425445
Drug: Lactose challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose challenge (2 g/kg) in lactose-intolerant children
Study: 8425445
Drug: Lactose challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose challenge (2 g/kg) in normal children
Study: 2906174
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg four times daily plus placebo
Study: 2906174
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg four times daily plus famotidine 40 mg once daily
Study: 21937568
Drug: Oxycodone/naloxone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone prolonged-release tablets (OXN PR)
Study: 21937568
Drug: Oxycodone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone prolonged-release tablets (OxyPR)
Study: 16054413
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (subcutaneous injections of GH 0.03 IU/kg/daily) for 5 days
Study: 16054413
Drug: IGF-I treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I treatment (continuous subcutaneous infusion of 5 microg/kg/h recombinant IGF-I) for 5 days
Study: 9522112
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker therapy
Study: 7877347
Drug: Carbimazole (decreasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole (decreasing doses)
Study: 7877347
Drug: Carbimazole (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole (high doses) plus Levothyroxine
Study: 1688617
Drug: MACOP-B chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACOP-B chemotherapy regimen (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Study: 1688617
Drug: MACOP-B chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACOP-B chemotherapy regimen
Study: 31297962
Drug: ICIs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICIs plus chemotherapy
Study: 22268699
Drug: Fractionated CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated CO2 laser therapy
Study: 15726120
Drug: EoP (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EoP (Cisplatin plus oral etoposide); etoposide 50 mg p.o. twice a day for 7 days, cisplatin 70 mg/m² i.v. on day 1, repeated every 3 weeks.
Study: 15726120
Drug: Paclitaxel; 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel; 175 mg/m² i.v. on day 1, repeated every 3 weeks.
Study: 12799102
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with conjugated estrogen and medroxyprogesterone for 3 months
Study: 8888304
Drug: Upright biological-motion
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upright biological-motion displays
Study: 8888304
Drug: Inverted biological-motion
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverted biological-motion displays
Study: 27890050
Drug: Interprofessional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional medication management
Study: 20672451
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine + zidovudine + lamivudine
Study: 12028899
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) 4.5 MU/daily for 24 weeks, followed by 4.5 MU/48 hours for a further 24 weeks (if ALT was normal)
Study: 6966882
Drug: terodiline 12.5
Normalized name: terodiline 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terodiline 12.5 mg twice daily
Study: 30362650
Drug: CAD/CAM-processed implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD/CAM-processed implant crowns
Study: 24531123
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g dark chocolate
Study: 24531123
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g white chocolate (control)
Study: 24603643
Drug: NEPA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA (300 mg netupitant + 0.50 mg palonosetron)
Study: 22871128
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate supplementation (600 mg·kg(‐1); CIT group)
Study: 18292704
Drug: Laboratory research
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory research and treatment trials for marijuana dependence; specific interventions not detailed.
Study: 16801747
Drug: Local guidelines,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local guidelines, de-escalation, rotation and association therapies
Study: 12546525
Drug: 5-FU 400
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m2 (group A)
Study: 12546525
Drug: 5-FU 500
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 500 mg/m2 (group B)
Study: 12546525
Drug: 5-FU 600
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 600 mg/m2 (group C)
Study: 10643517
Drug: Tamoxifen or
Normalized name: tamoxifen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen or interferon therapy
Study: 10643517
Drug: Extracorporal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporal shock wave therapy
Study: 2291867
Drug: Captopril (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5, 25, and 50 mg)
Study: 6114712
Drug: Combined H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined H1 (hydroxyzine hydrochloride) and H2 (cimetidine) antihistamines
Study: 6114712
Drug: H1 antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 antihistamines alone
Study: 31199705
Drug: Huoxin formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxin formula (13.5 g granules dissolved in 150 mL warm water, twice a day)
Study: 31199705
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only cardiovascular drugs)
Study: 28029540
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of combined Haemophilus influenzae type b and MenC‐tetanus toxoid vaccine (Hib‐MenC‐TT)